CSIR launches Ayurvedic anti-diabetic drug BGR-34
1. Developed jointly by NBRI & CIMAP, research units of CSIR
2. Scientifically validated for its efficacy and safety
3. Price only Rs 5/- per Tablet.
Council for Scientific and Industrial
Research (CSIR), today launched BGR-34 - country’s first anti-diabetic
ayurvedic drug with DPP4 inhibitory Activity. BGR-34, designed for type 2
Diabetes mellitus has been scientifically validated for its efficacy and
safety. BGR-34 is developed jointly by National Botanical Research Institute
(NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the
research units of CSIR, Govt. of India situated at Lucknow. Passing its larger benefits to people, BGR-34 has been
economically priced at Rs. 5 per tablet as compared to latest DPP4 inhibitors
globally. BGR-34 is now available on all major chemist counters of Kerala.
Speaking on the occasion Dr.A.K.S. Rawat, Sr. PrincipalScientist, CSIR-NBRI said “6 crore of
the adult Indian population has been found to be diabetic and there is no
effective solution for diabetes as yet. We are sure that eminent medical
professionals will recommend it to their patients suffering from type 2
Diabetes mellitus for quicker and consistent response. CSIR's premier research
institutions have developed and established the efficacy of BGR-34. The modern
diabetes drugs are known for side-effects and toxicity while BGR-34 works by
controlling blood sugar and limiting the harmful effects of other drugs."
The scientists of NBRI and CIMAP, joined
hands in developing an effective, safe, patient friendly solution towards
management of type 2 Diabetes mellitus. They had in-depth study of over 500
renowned ancientherbs and finally identified the 6 best herbs listed in
Ayurvedic ancient texts for various ailments and indications namely Daruharidra
(Berberisaristata), Giloy (Tinosporacordifolia), Vijaysar (Pterocarpus marsupium), Gudmar (GymnemaSylvestre), Majeeth (Rubiacordifoila) and Methika (Trigonellafoenum-graecum) to be combined
in different fractions &quantity and processed meticulously to develop a
marvelous anti-diabetic formulation. The herbs were further subjected to
optimization studies to establish the right proportion.
Dr Ch V Rao, Principal Scientist
CSIR-NBRI,said, "BGR-34
is a unique product that manages the lives of human suffering diabetics. One of
the critical ingredients inhibits DPP-4 and enhances insulin secretion. The
product passed several battery of tests and showed hypoglycemic activity in
experimental subjects."
Pre-clinical
studies of this antidiabetic formulation revealed significant reduction in high
blood sugar level in diabetes induced experimental subjects, with the activity
being comparable with the reference standard anti-diabetic allopathic drug.
Besides, the drug was found to improve LFTs,KFT’s and lipid profile
significantly.It also provided the much needed pronounced antioxidant
protective activity. No untoward effects were observed during the course of
study. Clinical
studies with BGR-34 have also revealed significant anti-diabetic activities
with no untoward effects observed.
For the purpose ofquality commercial
production and extended distribution, Aimil Pharmaceuticals (I) Ltd, the
organization well known for its innovative, quality Herbal / Ayurvedic products,has
been transferred the rights & technical knowhow to produce and market it
for medical use. The company is manufacturing BGR-34 at its state of the art
manufacturing units, which are well equipped with latest technology for
manufacturing quality medicines with astringent most quality control measures.
Mr. K. K. Sharma, Managing director of AIMIL
Pharmaceuticals, said "We are happy to be partner with institutes of such
repute for passing on its benefits to the people. We have decided to launch this marvellous
anti-diabetic product in the brand name BGR-34, standing for Blood Glucose
Regulator with 34 identified active phyto-constitutents from herbal
resources. With a strong marketing distribution network spread all over the
country, Aimil is strongly committed to carry forward the marvellous benefits
of this novel research to the suffering masses all throughout the country and
abroad."
Aimil
Pharmaceuticals, already had one successful technological collaboration with
DRDO (Defence Research and Development Organization, Govt. of India) yet another
premier research institute in the country, for effective and safe treatment of
leukoderma, still considered to be a big challenge to address. The product for leucoderma was successfully launched in the market in the
name Lukoskin, bringing smiles for the patient suffering from the social
stigma, leucoderma. In appreciation to its research work and commitment to
develop high quality innovative drugs, Aimil Pharmaceuticals has been bestowed
with 3 national awards from Govt. of India for manufacturing herbal medicines
of outstanding quality and also for research and development activities.
For more details please contact
Vishal Mishra
Kaivalya Communication
8756000222
Comments
Post a Comment